---
title: "Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant In Adults With Idiopathic Pulmonary Fibrosis Met Primary Endpoint"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301578258.md"
datetime: "2026-10-12T10:52:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301578258.md)
  - [en](https://longbridge.com/en/news/301578258.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301578258.md)
generator: "portal-rs"
---

# Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant In Adults With Idiopathic Pulmonary Fibrosis Met Primary Endpoint

Oct 12 (Reuters) - Bristol-Myers Squibb Company (BMY.N) :

-   BRISTOL MYERS SQUIBB ANNOUNCES PHASE 3 ALOFT-IPF TRIAL EVALUATING ADMILPARANT IN ADULTS WITH IDIOPATHIC PULMONARY FIBROSIS MET PRIMARY ENDPOINT
-   BRISTOL-MYERS SQUIBB COMPANY - ADMILPARANT 60 MG DOSE SHOWS STATISTICALLY SIGNIFICANT FVC IMPROVEMENT AT WEEK 52 VERSUS PLACEBO
-   BRISTOL-MYERS SQUIBB COMPANY - ADMILPARANT DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE
-   BRISTOL-MYERS SQUIBB COMPANY - ADMILPARANT 120 MG DOSE SLOWED FVC DECLINE BUT NOT STATISTICALLY SIGNIFICANT
-   BRISTOL-MYERS SQUIBB COMPANY - ADMILPARANT PHASE 3 ALOFT-PPF TRIAL TOPLINE RESULTS EXPECTED EARLY 2027

Source text:

Further company coverage: (BMY.N)

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

- [Bristol-Myers Spokesperson Says Grade 5 Event That Was Disclosed As Part Of Data Disclosure At Ms Toronto Occurred After Trial Pause](https://longbridge.com/en/news/302909326.md)
- [Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?](https://longbridge.com/en/news/300448973.md)
- [Bristol Myers Squibb says ZENBEXUS combo cuts multiple myeloma progression risk 51% in Phase 3 EXCALIBER-RRMM trial](https://longbridge.com/en/news/301263394.md)
- [BUZZ-Bristol Myers rises on positive trial results for cancer and lung disease drugs](https://longbridge.com/en/news/301590676.md)
- [Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%](https://longbridge.com/en/news/301304214.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**